Allogenic NK Cells / Kian Immune Cell Company - LARVOL DELTA

Efficacy of Intrathecal Injection of allogeneic natural killer cells in high-grade brain tumors (an interim analysis) (ESMO Asia 2025) - P2 | "Our results reveal the significant potential of allogeneic NK cells to enhance survival rates, particularly in pediatric patients with HGBT. The findings underscore the importance of intrathecal delivery that facilitates a concentrated presence of allogeneic NK cells at the tumor site, minimizing the dilution effects commonly associated with systemic administration. This targeted approach is essential for developing effective treatment protocols."

Clinical • Brain Cancer • Oncology • Solid Tumor

Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Marzieh Ebrahimi | Trial completion date: Feb 2025 ➔ Nov 2027 | Trial primary completion date: Feb 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor